Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data

Abstract

Clinical trials did not demonstrate an increased risk of hypertension with erenumab compared with placebo, and AE rates of hypertension reported with erenumab in the postmarketing setting were generally low. Additional data are needed to fully characterize the extent to which hypertension is a risk associated with erenumab.